Table 1.

Demographic and Methodological Overview of the Study.

Parameter	Details
Total Subjects	48
Duration of Follow-Up	12 months (21st March 2021 to 6th January 2023)
Vaccine Administered	Pfizer-BioNTech BNT162b2 COVID-19 vaccine
Gender Distribution	Females: 22 (45.8%), Males: 26 (54.2%)
Age Range	19 - 49 years
Median Age	30 years (IQR: 25-35.3)
Baseline S-IgG Classification	43 subjects classified (20 S-IgG-, 23 S-IgG+)
S-IgG Cut-off OD for Baseline Classification	≥ 0.432 (Positive), < 0.432 (Negative)
Note	5 subjects had no day 0 (D0) sample

This table summarizes the demographics and baseline characteristics of the 48 participants enrolled in the study.